Clinical Trials
Below are current clinical trials.
273 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.
-
Rochester, Minn.
This clinical trial is studying biomarkers in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effective treatment.
-
Rochester, Minn.
608 patients with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study and receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.
-
Rochester, Minn.
The purpose of this study is to validate the BinaxNOW™ COVID-19 Ag Card in the asymptomatic COVID-19 screening population.
The BinaxNOW™ COVID-19 Ag Card is a useful tool for the rapid detection of SARS-CoV-2 and screening for COVID-19 in both symptomatic and asymptomatic patient populations.
-
Scottsdale/Phoenix, Ariz.
This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection.
All subjects will have additional PK and Immunogenicity blood samples collected.
-
Rochester, Minn.
This study will be a retrospective and prospective analysis of patients with Post-COVID-19 symptoms that persist for greater than 28 days that are seen in the PCoCC (Post COVID Care Clinic), CARP, Pulmonary for post COVID clinic, Neurology, or approval by the MAGPIES research group.
Data for the registry will be aggregated from the EHR and by questionnaires. This data can be used to better guide strategic and tactical decisions as clinicians and healthcare managers respond to the rapidly evolving Post-COVID-19 patients.
The biobank will be optional for the participant and is designed to prospectively collect research biospecimens from Post-COVID-19 with symptoms that persist for greater than 28 days.
-
Rochester, Minn.
The purpose of this study is to prospectively clarify the long-term consequences of SARS-CoV-2 infection in the CNS with multi-modal magnetic resonance (MR) imaging tracking structural, microstructural, vascular and biochemical changes.
COVID-19 increases the risk of developing long-term inflammatory, neurodegenerative and cerebrovascular consequences.
-
Scottsdale/Phoenix, Ariz.
This is a Phase IV randomized, double-blinded, placebo-controlled study in 1000 individuals aged 18 years or older, with community acquired pneumonia (CAP) who meet all eligibility criteria in endemic regions. This study is designed to provide data on the effectiveness of early antifungal treatment (Fluconazole, 400 mg/day) for coccidioidomycosis pneumonia (also referred to as Valley Fever (VF) Pneumonia or acute onset valley fever) vs. placebo in subjects with coccidioidomycosis pneumonia. Patients who are prescribed antibacterials by their health care provider for acute CAP will be randomized to receive either placebo or 400 mg/day of fluconazole for 42 days. The primary objective is to assess the clinical response of early empiric antifungal therapy with fluconazole through Day 22 in subjects with coccidioidomycosis pneumonia and are compliant with the study intervention.
-
Rochester, Minn.
The purpose of this study is to evaluate the new QFT-Plus assay compared to the QFT-Gold assay and the tuberculin skin test results (as available) for the detection of tuberculosis without symptoms in high-risk patients.
-
Rochester, Minn.
What is the difference in the outcomes of patients treated with an articulating antibiotic spacer versus a static articulating spacer in the setting of two stage exchange for an infected total knee arthroplasty?